Coverage decisions and utilization management opportunities The latest report released from the Institute for Clinical and Economic Review (ICER) 2 highlights that on an individual basis, therapies like semaglutide and tirzepatide may be considered cost-effective for the treatment of obesity
C th c cc tc dng sau: H tr tng cng chc nng gan, thn, mt, phi, h sinh sn khi tc ng ca cc gc t do, hoc b nhim c
The relatively recent introduction of Tirzepatide into clinical practice inherently constrains both sample size and follow-up duration compared to more established medications, potentially limiting our ability to detect rare events or effects that may emerge only after longer exposure periods
According to NielsenIQ data, users spent 14.5% less in the category after starting the treatment, while nonalcoholic wine and beer purchases among the group ballooned by 1,158% and 935%, respectively, said the Post